ADDEX THERAPEUTICS 2 RSS Feed | Nachrichten - www.finanzen.net

Addex Therapeutics stellte das Zahlenwerk zum vergangenen Quartal vor

Sat, 02 May 2026 06:35:06 +0200

Addex Therapeutics hat am 30.04.2026 die Bücher zum am 31.12.2025 abgelaufenen Quartal geöffnet.Dabei wurde ein Verlust je Aktie von 1,50 USD ausgewiesen. Im Vorjahresquartal waren -1,370 USD je Aktie erwirtschaftet ...

Press Release: Addex Reports Full Year 2025 -2-

Thu, 30 Apr 2026 06:59:49 +0200

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words "may," "will," "could," ...

Press Release: Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model

Wed, 29 Apr 2026 06:59:51 +0200

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - https://www.globenewswire.com/Tracker?data=ZV0DB8nXK5jXOvYFLuX339bL7LceuQhPmdmWzvQGnGEttSJmV5WGU4wY2y_akXT7C8W0rznNFv2tbKtsMwueIX86MtmsR9a21Ngv1jG857PMuskB_JOG4GhH3LuTKJkd ...

Press Release: Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026

Thu, 23 Apr 2026 06:59:49 +0200

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026 - https://www.globenewswire.com/Tracker?data=Qm7by9FddKkOerMGBk3GBx2g2gsU3kITGs2V49zotNyMWmUcRk-66nBTtBvX-kor7JIllf_Ouh-FaPRHtqjrlyP6l7TGKpNrXpi5kAPWGJs6ltEIU60Xziub1nkUaBCM ...

Press Release: Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model

Tue, 21 Apr 2026 06:59:42 +0200

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - https://www.globenewswire.com/Tracker?data=1O9Ugb07lLu1EXydV_jV3EeLb4SlAtREr3mqnAZMdi4BMPNHDThIt1ddy8Wz4fB-ekBjsYjIByy85_pt9MVN1GIJdEqv9mHs9AoOl8acEpcKSMMG5WZNNneE2g8pj3FG ...

Press Release: Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Rel...

Tue, 03 Feb 2026 06:59:52 +0100

Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - https://www.globenewswire.com/Tracker?data=9oqhfe7nilAz9wRZfFH1qtLKm4htn4Luf36xYpupCm1Q9LUOhoaTYXw99Ovpn8Zk5d_KwG4iYO-Xn3AaV2JoaYZRW1Ka91dDM0TiyoTAlII0N7JsM3Zp54jNpNtioYXU ...

Press Release: Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Wed, 07 Jan 2026 06:59:42 +0100

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - https://www.globenewswire.com/Tracker?data=NfweDVg9BAdfQtXZ1wmoyMfW6fBteEhkJep6V2DV5C5nOggy5dbCksQUIazl1pYXlRPAIsYoj_EtIJxPYfpsO1Lqm7bH_qigoMdh0QkCzRc7zhzOxk6hp_QMJ9FVQDB1 ...